The Press Room

The Barbara Ann Karmanos Cancer Institute welcomes Morhaf Al Achkar, M.D., Ph.D., MSCR, FAAFP, as the associate center director for Education. Dr. Al Achkar brings over 10 years of experience in education and teaching, research, and clinical family. He also brings valuable personal experience to his new role as a seven-year stage IV lung cancer survivor. “It has been a pleasure and an exciting transition moving from Seattle to Detroit to join the team here at Karmanos,” said Dr. Al Achkar. “I have begun...

Michigan Chronicle About 90% of liver cancer cases are hepatocellular carcinoma (HCC). The Michigan Chronicle looks at how more African Americans are diagnosed with liver cancer than White Americans. The new TheraBionic P1 medical device that Karmanos will offer patients in 2024 is FDA approved to treat this advanced-stage liver cancer after patients have failed first- and second-line treatment options. Boris Pasche, M.D., Ph.D., FACP , president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D. , m...

The Barbara Ann Karmanos Cancer Institute , along with cancer centers and other organizations across the nation, recognizes November as Pancreatic Cancer Awareness Month. As its name indicates, pancreatic cancer originates in the pancreas, an organ that sits behind the stomach. The pancreas aids in digestion and helps regulate blood sugar. About Pancreatic Cancer Exocrine cells make up the majority of the pancreas. When these cells grow out of control, adenocarcinoma of the pancreas occurs. Pancreatic a...

Society of Nuclear Medicine & Molecular Imaging The Society of Nuclear Medicine & Molecular Imaging featured research recently published by Karmanos scientists. Nerissa Viola, Ph.D., leader of the  Molecular Imaging Research Program  at Karmanos and associate professor at Wayne State University School of Medicine, and several Karmanos researchers and physicians published “Detection of IL12/23p40 via PET visualizes inflammatory bowels disease"   in the Journal of Nuclear Medicine i...

The Barbara Ann Karmanos Cancer Institute , along with cancer centers and other organizations nationwide, recognize November as Lung Cancer Awareness Month. Lung cancer is the second most common cancer among women and men, not including skin cancer. For women, breast cancer is more common while prostate cancer is the most common cancer for men. Lung Cancer Facts and Figures About 238,340 new cases of lung cancer will be diagnosed in 2023. About 127,070 deaths will result from lung cancer in 2023. Lung c...

DBusiness Karmanos Cancer Institute in Detroit will be the first provider to offer the TheraBionic P1 medical device for the treatment of advanced hepatocellular carcinoma, the most common type of liver cancer.  Boris Pasche, M.D., Ph.D., FACP , president and CEO at Karmanos, and Anthony Shields, M.D., Ph.D. , medical oncologist and leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team , explain the device's benefits to patients 18 years and older who have failed first- ...

“We’re excited to be the first cancer hospital in the United States to offer this innovative therapy that is safe, well tolerated, and has the clinical benefit of reducing tumor growth.” Karmanos Cancer Institute , the largest provider of cancer care and research in Michigan and part of McLaren Health Care, announced today that it will be the first provider in the country to offer patients the new FDA-approved TheraBionic P1 device for the treatment of advanced hepatocellular carcinoma (HCC), the most c...

WXYZ The Million Meter Row Challenge drew tens of participants to CrossFit in the D. Teams were to collective row one million meters to raise funds for Karmanos Cancer Institute's CAPABLE program. Watch the story here .  Learn more about CAPABLE here .

Patient Power Lydia Choi, M.D. , breast surgeon and member of the Breast Cancer Multidisciplinary Team at Karmanos, explains the advantages and disadvantages of deciding to have a lumpectomy to treat breast cancer. Read the article  here .

CBS News Detroit November is Pancreatic Cancer Awareness Month. Najeeb Al Hallak, M.D., MS , medical oncologist and member of the Gastrointestinal and Neuroendocrine Oncology and the Phase 1 Clinical Trials Multidisciplinary Teams at Karmanos, explains the symptoms of pancreatic cancer, clinical trials and some success stories of a few of his patients. Watch the interview here .